[go: up one dir, main page]

DE60114027D1 - Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion - Google Patents

Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion

Info

Publication number
DE60114027D1
DE60114027D1 DE60114027T DE60114027T DE60114027D1 DE 60114027 D1 DE60114027 D1 DE 60114027D1 DE 60114027 T DE60114027 T DE 60114027T DE 60114027 T DE60114027 T DE 60114027T DE 60114027 D1 DE60114027 D1 DE 60114027D1
Authority
DE
Germany
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improving cognitive
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60114027T
Other languages
English (en)
Other versions
DE60114027T2 (de
Inventor
N Fedde
T Perez
F Tooley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of DE60114027D1 publication Critical patent/DE60114027D1/de
Application granted granted Critical
Publication of DE60114027T2 publication Critical patent/DE60114027T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60114027T 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion Expired - Fee Related DE60114027T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28
US228738P 2000-08-28
PCT/US2001/026760 WO2002017895A2 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Publications (2)

Publication Number Publication Date
DE60114027D1 true DE60114027D1 (de) 2006-02-23
DE60114027T2 DE60114027T2 (de) 2006-07-13

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114027T Expired - Fee Related DE60114027T2 (de) 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (de)
EP (1) EP1313485B1 (de)
JP (1) JP2004507495A (de)
AT (1) ATE306272T1 (de)
AU (1) AU2001285318A1 (de)
CA (1) CA2419256A1 (de)
DE (1) DE60114027T2 (de)
DK (1) DK1313485T3 (de)
ES (1) ES2251505T3 (de)
WO (1) WO2002017895A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193172B2 (en) 2001-11-23 2012-06-05 Pop Test Cortisol Llc Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
NZ548754A (en) * 2002-04-26 2008-06-30 Schering Aktiengellschaft Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
JP2006508945A (ja) * 2002-11-05 2006-03-16 シエーリング アクチエンゲゼルシャフト 抗−アルドステロン性プロゲスチンを用いての心血管保護
WO2004060400A1 (ja) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp 上皮成長因子受容体を分子標的とする抗精神病薬
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CA2824344A1 (en) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
ES2592818T3 (es) 2011-10-13 2016-12-01 Merck Sharp & Dohme Corp. Antagonistas del receptor de mineralocorticoides
EP2765859B1 (de) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralkortikoid-rezeptorantagonisten
US9193717B2 (en) 2011-10-13 2015-11-24 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
US10039772B2 (en) * 2015-11-13 2018-08-07 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
AU538186B2 (en) * 1980-03-07 1984-08-02 Scotia Holdings Plc Prostaglandin precursors
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EP0944644B1 (de) * 1996-12-11 2002-10-02 G.D. Searle & Co. VERFAHREN ZUR HERSTELLUNG VON 3-KETO-7alpha-ALKOXYCARBONYL- delta4,5-STEROIDEN SOWIE ZWISCHENPRODUKTE
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
KR20010100986A (ko) * 1998-11-06 2001-11-14 로저 에이. 윌리암스 심장혈관 질병으로 인한 이병률 및 사망률 감소용안지오텐신 전환 효소 억제제 및 알도스테론 길항제의결합 치료방법
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1165136E (pt) * 1999-03-05 2004-02-27 Searle Llc Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular

Also Published As

Publication number Publication date
WO2002017895A3 (en) 2003-02-06
ES2251505T3 (es) 2006-05-01
US20020111337A1 (en) 2002-08-15
ATE306272T1 (de) 2005-10-15
DE60114027T2 (de) 2006-07-13
EP1313485B1 (de) 2005-10-12
JP2004507495A (ja) 2004-03-11
WO2002017895A2 (en) 2002-03-07
CA2419256A1 (en) 2002-03-07
AU2001285318A1 (en) 2002-03-13
EP1313485A2 (de) 2003-05-28
DK1313485T3 (da) 2005-12-27
US20060058274A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
DE60114027D1 (de) Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
EP1156792A4 (de) Methoden und zusammenstellungen zur behandlung des reizdarmsyndroms unter verwendung von niedrigdosierten antagonisten des opioidrezeptors
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
EA200400029A1 (ru) КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА АЛЬДОСТЕРОНА И ИНГИБИТОРА ГМГ-КоА-РЕДУКТАЗЫ
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE438405T1 (de) Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
MXPA06000664A (es) Antagonistas del receptor muscarinico de acetilcolina.
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
MA26907A1 (fr) Cyclohexylamines bicycliques et leur utilisation comme antagonistes de recepteurs de nmda.
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
PL371128A1 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
NZ513679A (en) Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee